Biz3a.jpeg
Biz2b.jpg
Biz1a.jpeg

 

Officers, Directors

Consultants and Advisers

Marc J. Bielski, MD (Co-founder MyoCardioCare, Inc. U.S.; Director) has a strong background in the sciences and research, including emerging technologies. Following graduation from New York’s University of Rochester, Dr. Bielski participated in stem cell research in cancer immunology and immunotherapy at the M.D. Anderson Cancer Center in Houston, Texas. Following completion of numerous research projects, including publication of several articles, he attended the University of Texas Health Science Center School of Medicine at San Antonio. After moving to New York City, Dr. Bielski became a general, holistic physician working in practice with other holistic practitioners and, later, in his own practice within a holistic medical clinic. His areas of expertise include gastrointestinal illnesses and various types of chronic pain. His interests in research, especially bringing cutting-edge medical technologies to market, have focused his attention on emerging technologies rather than out-patient care. Dr. Bielski has written numerous articles and manuscripts. He has lectured on holistic medicine and other health-related topics and has made guest appearances on numerous syndicated radio shows.

Susan Doctrow, PhD (SBIR Advisor/ Consultant/ Reviewer) has broad experience directing entrepreneurial biotechnology/pharmaceutical research, including cross-disciplinary teamwork in drug discovery, lead optimization, preclinical drug development and alliance management. Further experience on a medical school faculty directing government-funded research on mitigation of radiation injury, diseases associated with oxidative stress and mitochondrial injury. Strong communication and critical thinking skills to advise on regulatory documents for drug development, SBIR/STTR grantsmanship, scientific journal publication strategies, medically relevant reviews and strategic scientific/business presentations. Dr. Doctrow has served as Principal Investigator for federal grant and subcontract awards totaling ~$7.2M and has Peer reviewed SBIR/STTR grant applications and scientific manuscripts for over 15 years. She is Inventor of 8 issued US patents on experimental therapeutic agents (and associated foreign filings and published applications), is the author of 65+ scientific publications, including primary journal articles and reviews and editor of a book, Medicinal Inorganic Chemistry (American Chemical Society, 2005). Dr. Doctrow received her PhD in Biochemistry from Brandeis University and her BA degree in Biology from the University of Rochester. She served as a Postdoctoral Research Fellow at Boston Children’s Hospital where her work focused on angiogenesis, cell biology.

William Ker Ferguson, PhD (Chief Operating Officer; Principal Investigator) is an accomplished entrepreneurial executive with a proven management track record and demonstrated business acuity. He is an early-stage new ventures leader and startups strategy specialist with experience across the innovation ecosystem. Doctor Ferguson was the CEO of Exscien Corporation whose goal is to repair DNA damage to reduce cardiac tissue injury and improve outcomes in cardiovascular diseases. mtDNA damage initiates the critical path and progression of many disease states e.g., ischemic stroke, acute and chronic heart failure, cancer, diabetes, macular degeneration, neurodegenerative diseases, arthritis, reperfusion injury, sepsis, etc. – all which represent target market applications. Dr. Ferguson’s responsibilities at Exscien include end-to-end management of all corporate and governance functions (i.e., strategy, budget setting, finance, operations, R&D). Previously at the University of South Alabama Dr. Ferguson’s responsibilities encompassed executive management of the University’s portfolio of intellectual property assets and research park enterprise (patents, early-stage technology development, business strategy, budget, finance, operations, staffing, marketing, etc.). Dr. Ferguson’s PhD degree in Philosophy was awarded at the University of Southern Mississippi. He also has undergraduate and MBA degrees in accounting and finance from Western University.

James M. Jansing, JD (Corporate Counsel---Keating Muething & Klekamp PLL) has represented MCCI since 2015 on a variety of corporate matters, both domestically and internationally including financing transactions, shareholder matters and general document preparations and reviews. Jansing, a member of the 125-person firm’s Board of Directors also serves on the Women’s Initiative Committee. He received his B.S. degree (magna cum laude) from the University of Cincinnati and his J.D. degree from that same school’s College of Law. He has been listed in Best Lawyers in America consecutively from 2010, been named to Ohio Super Lawyers and is AV Preeminent Peer Review rated by Martindale-Hubbell.

Pratap S. Khanwilkar, PhD, MS, MBA (Cardiac Consultant) is Vice-President, Product Development of InCube Labs LLC, San Jose, CA & San Antonio TX, a multi-product medical device and related product incubator where he leads engineering, manufacturing and QA aspects of product development, builds and manages engineering, related support organizations, provides technical and business leadership in product R & D and is involved with the development and implementation of pre-clinical and clinical studies. Dr. Khanwilkar is also adjunct professor in the Department of Bioengineering at the University of Pittsburgh. He also was Co-Founder, President, CEO and Chairman of MedQuest Products and invented, developed and sold four MedTech products including a 510K Class II device. He helped raise capital to develop a long-term implantable LVAD for late-stage CHF (congestive heart failure). He led MedQuest’s acquisition by NASDAQ-listed World Heart. Dr. Khanwilkar received a B. Tech degree in Electrical Engineering (with honors) from the Indian Institute of Technology, M.S. and PhD degrees in Bioengineering and an M.B.A. degree from the University of Utah. He has received numerous Honors, recognitions, and awards over his career.

John Lanzafame (Director) was the first President of MyoCardioCare, Inc., having served in that role from the company’s formation in 2009 through 2014 and immediately prior served as CEO of Biophan Technologies, Inc., a public medical technology development company from which MyoCardioCare acquired the technology and intellectual property used in the development of its medical device for the treatment of cardiac arrest. Lanzafame currently is the Director of Commercial and Laboratory Operations for iuvo BioScience, a private Rochester, NY-based organization focused on testing services for the medical device and pharmaceutical industries.  He brings over twenty-five years of experience in the medical device sector in both public and private organizations.  He has extensive experience in business development, sales, marketing and executive-level management with a strong technical background in product development and commercialization.

 

John has negotiated dozens of strategic partnerships and technology licenses between diverse entities ranging from startups to Fortune 50 companies to leading government research laboratories and universities.  He has also led product development activities for Class 3 to Class 1 medical devices and pharmaceutical formulations for novel oncology treatments. Lanzafame has also filled a variety of other roles in both public and private companies, including CEO of Isoflux Incorporated, a private technology company serving the medical device and optics industries, and President of STS Biopolymers, Inc., a private OEM company that developed high performance polymer coatings for the medical device industry, including lubricious coatings for catheters and guidewires and drug eluting coatings for stents and central catheters.  He has also served on the board of directors of several private and public companies. John holds a bachelor’s degree in chemical engineering from the University of Dayton and a master’s degree in industrial engineering management from Rochester Institute of Technology.

Michael J. Nickerson, JD (Patent Counsel—Basch & Nickerson) has represented MCCI since 2010 on a variety of patent-related issues. The firm specializes in the preparation of patent applications, the prosecution of application before the U.S. Patent & Trademark Office, as well as the licensing and enforcement of patents and other intellectual property rights. Nickerson has over 20 years’ experience as a patent attorney. Before starting the firm, he served as Senior Patent Counsel at Xerox, as an associate in a Washington D.C. law firm, and as a Patent Examiner with the U.S. Patent and Trademark Office, after serving a brief time as an engineer with the US Department of Defense. His JD degree is from George Mason University School of Law. He also earned a BSEE degree in Electrical Engineering from Cornell University.

Michael Rosen (Advisor to MyoCardioCare, Inc.), a Partner with A-MEDICA, a Brussels, Belgium Life Sciences & Health Tech Business Development organization is an experienced professional with a demonstrated history in the international life sciences and medical device industries. Rosen also focuses on Entrepreneurship, International Business, Venture Capital and other Funding Solutions, Market Access and Sales. He has experience across the device spectrum running from protyping through commercialization. Rosen has worked with MCCI since 2014 and holds a Civilekonom (Business and Finance) degree from the Stockholm School of Economics.

Frank W. Terrizzi, JD (Founder and CEO, MyoCardioCare, Inc. U. S.; Chairman-Board of Directors) collaborated on the 2009 founding of MCCI, has more than 40 years of experience in the investment management industry, ranging from larger established firms to start-up organizations. He began his career at Scudder, Stevens and Clark in Cincinnati where he managed institutional portfolios and created a research product focused on emerging growth companies in which he was the principal analyst; thereafter, he was recruited by The Central Trust Company (now PNC Bank) where, as director of research, he was a principal in the launch of a wholly owned bank subsidiary dedicated to investment in emerging growth companies. In 1978, Terrizzi co-founded Renaissance Investment Management, an early adopter of algorithms to determine investment policy. In addition to creating the firm’s quantitatively based approach, he served as both President and Managing Director and assisted in raising more than $1.5 billion. In 1995, he sold the firm to Affiliated Managers Group, a New York Stock Exchange-listed company organized to acquire mid-sized investment management firms. Terrizzi holds a bachelor’s degree from Miami University in Oxford, Ohio, and a Juris Doctor degree from The Ohio State University College of Law. He has served as an “Executive in Residence” at Miami, been a member of Miami’s Business Advisory Council and a guest lecturer on business organization and entrepreneurship. He has been a regular speaker at investment conferences, appeared on radio and television programs discussing investments. In his spare time, he is a published author.